Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells.

Abstract:

:Ginsenoside Rg3 is an effective chemical component extracted from the red Panix. The experiment demonstrated that it might effectively inhibit proliferation and metastasis of tumor cells. The exact molecular mechanism of Rg3 remains unclear so far. To further explore the antitumor function of Rg3, we investigated the in-vitro and in-vivo activity of Rg3 in the treatment of B16 melanoma cells, derived from C57BL/6 mouse, capable of forming tumor colonies in the lungs following intravenous injection. Cell proliferation was measured by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide assay. Morphological changes of cells were observed by staining with Giesma and Hoechst 33258. Cell cycle and apoptosis rate were analyzed by flow cytometry. The expression of caspase-3 and bcl-2 in cells was detected by immunocytochemistry and western blot analysis. We found that Rg3 could inhibit cell proliferation, regulate cell cycle, and induce cell apoptosis in vitro. B16 melanoma-bearing mice were used to evaluate in vivo the antitumor activity of Rg3. Mice that were injected with Rg3 showed significant inhibition of the tumor metastasis with lighter lung weight, lower density of microvessels, fewer metastasis nodules, and longer survival time than those in the control group (P<0.001). In conclusion, the results reveal that antitumor metastasis of Rg3 is also associated with inducing apoptosis, regulating cell cycle, and blocking angiogenesis in addition to inhibiting proliferation. This research might supply valuable data for chemotherapy with Rg3 in melanoma. Rg3 would turn out to be an anticancer drug with promising prospects.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Chen J,Peng H,Ou-Yang X,He X

doi

10.1097/CMR.0b013e32830b3536

subject

Has Abstract

pub_date

2008-10-01 00:00:00

pages

322-9

issue

5

eissn

0960-8931

issn

1473-5636

pii

00008390-200810000-00003

journal_volume

18

pub_type

杂志文章
  • Unmet information needs of patients with melanoma in Germany.

    abstract::There is a scarcity of available data on unmet information needs (UINs) of melanoma patients (MPs) from Germany and of MPs with clinical stage IV. In a multicenter cross-sectional survey, we explored the UINs of 529 MPs by applying a standardized questionnaire. Subgroup differences in scope and contents of UINs were d...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CMR.0000000000000464

    authors: Brütting J,Bergmann M,Garzarolli M,Rauschenberg R,Weber C,Berking C,Tilgen W,Schadendorf D,Meier F,NVKH supporting group.

    更新日期:2019-04-01 00:00:00

  • Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.

    abstract::The management of metastatic melanoma is a difficult matter. Nevertheless, the advent of target therapy has significantly improved patient outcome, provided that tumor molecular characteristics become available: the detection of drug-resistant clones can contribute to understanding the reasons for resistance onset, in...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000510

    authors: Scaini MC,Pigozzo J,Pizzi M,Manicone M,Chiarion-Sileni V,Zambenedetti P,Rugge M,Zanovello P,Rossi E,Zamarchi R,Facchinetti A

    更新日期:2019-02-01 00:00:00

  • MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.

    abstract::MAGE proteins have been identified as potential specific targets for cancer vaccination. Although MAGE-6 and MAGE-12 were originally identified in malignant melanoma there are no studies reporting the frequency of expression of these antigens in this malignancy. These are of relevance particularly for MAGE-6 as recent...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Gibbs P,Hutchins AM,Dorian KT,Vaughan HA,Davis ID,Silvapulle M,Cebon JS

    更新日期:2000-06-01 00:00:00

  • Molecular and immunohistochemical analyses of uveal melanoma patient cohort.

    abstract::Uveal melanoma is a rare form of melanoma and the most frequent primary eye malignancy in adults. The major molecular alterations underlying uveal melanoma pathogenesis affect mainly the GNAQ, GNA11, SF3B1, and BAP1 genes. In this study, we somatically genotyped 31 Brazilian uveal melanomas for BRAF, GNA11, GNAQ, SF3B...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000523

    authors: Sarubi HC,Pereira NB,Gomes CC,Gomez RS,Carmo ACM,Melo FM,Bastos-Rodrigues L,Pedrosa MS,Friedman E,De Marco L

    更新日期:2019-06-01 00:00:00

  • A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.

    abstract::A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/CMR.0000000000000556

    authors: Block MS,Nevala WK,Pang YP,Allred JB,Strand C,Markovic SN

    更新日期:2019-08-01 00:00:00

  • Statistical evaluation of epiluminescence microscopy criteria in the differential diagnosis of malignant melanoma and pigmented basal cell carcinoma.

    abstract::Pigmented basal cell carcinoma (PBCC) is a tumour with distinct clinical features which occasionally may be difficult to differentiate from malignant melanoma (MM). The purpose of this study was to re-examine the epiluminescence microscopy (ELM) criteria for PBCC and to determine their statistical significance in the ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199708000-00005

    authors: Püspök-Schwarz M,Steiner A,Binder M,Partsch B,Wolff K,Pehamberger H

    更新日期:1997-08-01 00:00:00

  • Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

    abstract::Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patient data using a pre...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000185

    authors: Ahmad SS,Qian W,Ellis S,Mason E,Khattak MA,Gupta A,Shaw H,Quinton A,Kovarikova J,Thillai K,Rao A,Board R,Nobes J,Dalgleish A,Grumett S,Maraveyas A,Danson S,Talbot T,Harries M,Marples M,Plummer R,Kumar S,Nathan

    更新日期:2015-10-01 00:00:00

  • Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.

    abstract::For the treatment of choroidal melanoma, palladium-103 (Pd) and ruthenium-106 (Ru) plaque brachytherapy shows reduced toxicity compared with the historical standard iodine-125. No report has directly compared the clinical outcomes between Pd and Ru, and the reasons for the selection of one over the other remain purely...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000420

    authors: Danish H,Ferris MJ,Balagamwala E,Switchenko JM,Patel KR,Choudhary M,Craven C,Mendoza P,Suh J,Bergstrom C,Grossniklaus HE,M Aaberg T Sr,Singh A,Crocker IR,Khan MK

    更新日期:2018-04-01 00:00:00

  • Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.

    abstract::Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or interferon-alpha (IFNalpha) as single drugs, or in combination, results in a response rate of approximately 15-20%. This study evaluated the activity and toxicity following treatment with a combination of DTIC, IFNalpha2b and verapamil (V...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200302000-00014

    authors: Andersson R,Ake Hofer P,Riklund-Ahlström K,Henriksson R

    更新日期:2003-02-01 00:00:00

  • Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

    abstract::The objective of this study was to identify novel tumor-suppressor genes in melanoma, using an integrative genomic approach. Data from: (i) earlier reports of DNA loss and gain in malignant melanoma accompanied by comparative genomic hybridization high-definition array data of the entire human genome; (ii) microarray ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328344a003

    authors: Mithani SK,Smith IM,Califano JA

    更新日期:2011-08-01 00:00:00

  • Alkylating benzamides with melanoma cytotoxicity.

    abstract::Radioiodinated N-(2-(diethylamino)ethyl)benzamides have recently been discovered as selective agents for melanotic melanoma and are used for scintigraphic imaging in nuclear medicine. Owing to the high binding capacity, benzamide derivatives conjugated with alkylating cytostatics were synthesized and tested for their ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200410000-00004

    authors: Wolf M,Bauder-Wüst U,Mohammed A,Schönsiegel F,Mier W,Haberkorn U,Eisenhut M

    更新日期:2004-10-01 00:00:00

  • Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.

    abstract::Recently, we reported on the associations of seven single nucleotide polymorphisms (SNPs) in the promoter region of MMP1 gene with susceptibility to cutaneous melanoma (CM). Considering the reported correlation between MMP1 expression and melanoma progression, we hypothesized that these promoter SNPs might affect CM p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32834fc46b

    authors: Liu H,Wei Q,Gershenwald JE,Prieto VG,Lee JE,Duvic M,Grimm EA,Wang LE

    更新日期:2012-04-01 00:00:00

  • In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity.

    abstract::When cancer cells, including melanoma cells, are genetically altered to secrete cytokines, irradiated and injected into subjects, long-term antitumour immunity is induced. Optimally, existing melanomas induced to produce cytokines in vivo could stimulate this same immune response. Although in vivo electroporation enha...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200012000-00010

    authors: Heller L,Pottinger C,Jaroszeski MJ,Gilbert R,Heller R

    更新日期:2000-12-01 00:00:00

  • Risk of cutaneous melanoma in a cohort of infertile women.

    abstract::We assessed the risk of cutaneous malignant melanoma associated with the presence of ovulatory abnormalities and with the use of ovulation-inducing agents (such as clomiphene citrate) in a cohort of 3,837 women evaluated at infertility clinics in Seattle, WA, between 1974 and 1985. Computer linkage with a population-b...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199504000-00009

    authors: Rossing MA,Daling JR,Weiss NS,Moore DE,Self SG

    更新日期:1995-04-01 00:00:00

  • Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

    abstract::The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine-dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine-dacarbazine toge...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0b013e328341445f

    authors: Bedikian AY,Johnson MM,Warneke CL,Papadopoulos NE,Kim KB,Hwu WJ,McIntyre S,Rohlfs M,Homsi J,Hwu P

    更新日期:2011-02-01 00:00:00

  • Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells.

    abstract::Melanoma cells are unusual because, unlike most epithelial tumours, constitutive expression of HLA class II antigens is common. We have previously demonstrated that a peptide-specific CD4+ T-cell clone proliferates briskly in response to peptide and HLA class II expressing melanoma cell lines derived from metastases. ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199904000-00010

    authors: Brady MS,Eckels DD,Lee F,Ree SY,Lee JS

    更新日期:1999-04-01 00:00:00

  • Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.

    abstract::Glutathione (GSH) is the major non-protein thiol in cells that plays a critical role against damage from electrophilic agents such as alkylating drugs. Selective therapeutic GSH elevation in normal but not in tumour cells has been suggested as a means of protecting host tissues against more intense doses of chemothera...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: del Olmo M,Alonso-Varona A,Castro B,Calle Y,Bilbao P,Palomares T

    更新日期:2000-04-01 00:00:00

  • Surgical margins in patients with cutaneous melanoma--assessing the adequacy of excision.

    abstract::Appropriate margins of excision for melanoma have been well defined on the basis of prospective clinical trials. Various factors may result in a discrepancy between the intended clinical margin and the pathologic margin ex vivo, however, making it difficult to determine whether adequate excision margins have been obta...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200512000-00009

    authors: Clausen SP,Brady MS

    更新日期:2005-12-01 00:00:00

  • Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma.

    abstract::Several comparative genomic hybridization studies provide evidence for overrepresentation of the long arm of chromosome 20 in malignant melanoma. These studies also suggest that chromosome 20q contains genes that may contribute to melanoma pathogenesis. To refine the region of 20q amplification and to identify potenti...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3280141617

    authors: Koynova DK,Jordanova ES,Milev AD,Dijkman R,Kirov KS,Toncheva DI,Gruis NA

    更新日期:2007-02-01 00:00:00

  • Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.

    abstract::Desmoplastic melanoma (DM) due to its rare and locally aggressive nature, can be difficult to study and to treat effectively. Whether the optimal treatment approach for these tumors should include adjuvant radiation has been unclear in the literature. In this retrospective study of the National Cancer Database, 2390 p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000532

    authors: Abbott JL,Qureshi MM,Truong MT,Sahni D

    更新日期:2019-08-01 00:00:00

  • Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.

    abstract::In this study, we aimed to evaluate the feasibility and efficacy of peptide-pulsed dendritic cell (DC) vaccine in combination with carboplatin and paclitaxel chemotherapy (DCCP) for patients with stage IV melanoma previously treated with dacarbazine-containing regimen. Six HLA-A24 and 3 HLA-A02 patients were treated w...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000342

    authors: Fukuda K,Funakoshi T,Sakurai T,Nakamura Y,Mori M,Tanese K,Tanikawa A,Taguchi J,Fujita T,Okamoto M,Amagai M,Kawakami Y

    更新日期:2017-08-01 00:00:00

  • A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

    abstract::We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion i...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000036

    authors: Lau DK,Andrews MC,Turner N,Azad AA,Davis ID,Cebon JS

    更新日期:2014-04-01 00:00:00

  • Surgical management of metastatic melanoma in the era of targeted systemic therapies.

    abstract::Treatment strategies for metastatic melanoma have changed markedly in recent times due to the advent of targeted systemic therapies. In addition to these developments, surgery remains a useful adjunct that can confer survival benefits in selected patients. In this review, we examine the current literature to highlight...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0000000000000128

    authors: O'Leary DP,Byrnes KG,Power DG,Redmond HP

    更新日期:2015-02-01 00:00:00

  • Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.

    abstract::Melanomas are promising targets for immunotherapy, as they express a number of tissue-specific antigens against which immune responses can be elicited. We have previously described transgenic mice in which malignant cutaneous melanomas are produced. The 1042 melanoma cell line, derived from a primary melanoma in one o...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200412000-00019

    authors: Milling SW,Sai T,Silvers WK,Mintz B

    更新日期:2004-12-01 00:00:00

  • Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

    abstract::Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of ipilimumab administ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000108

    authors: Berrocal A,Arance A,Lopez Martin JA,Soriano V,Muñoz E,Alonso L,Espinosa E,Lopez Criado P,Valdivia J,Martin Algarra S,Spanish Melanoma Group.

    更新日期:2014-12-01 00:00:00

  • A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.

    abstract::Conjunctival melanoma is a rare disease, and little is known about its molecular background. Here, we present the case of a 48-year-old patient with conjunctival melanoma and metachronic lymph node and skin metastasis with KRAS p.K117Y mutation in exon 4 in all the lesions. The cancer genome interpreter predicted this...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0000000000000423

    authors: Del Carpio Huerta LP,Mas Castells M,Anguera Palacios G,Sullivan I,Gonzalez Vidal A,Majem Tarruella M

    更新日期:2018-04-01 00:00:00

  • The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.

    abstract::Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and t...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.cmr.0000136707.60108.ab

    authors: Bafaloukos D,Tsoutsos D,Fountzilas G,Linardou H,Christodoulou C,Kalofonos HP,Briassoulis E,Panagiotou P,Hatzichristou H,Gogas H

    更新日期:2004-08-01 00:00:00

  • BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

    abstract::Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000214

    authors: Sloot S,Zager JS,Kudchadkar RR,Messina JL,Benedict JJ,Gonzalez RJ,DeConti R,Turner LM,McCardle T,Smalley KS,Weber JS,Sondak VK,Gibney GT

    更新日期:2016-02-01 00:00:00

  • Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group.

    abstract::The EORTC Melanoma Cooperative Group conducted a phase II trial (study number 18891) to study the effect of Toremifene in 45 patients with advanced, metastatic melanoma. Male and female patients, median age 61 (range 23-88) years received a mean total dose of 11 g (4.3-62.6) orally for at least 6 weeks. No objective r...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Kleeberg UR,Engel E,Bröcker EB,Avril F,Israels P,Weiss J,Kangas L,van Glabbeke M,Lentz MA

    更新日期:1993-04-01 00:00:00

  • Effect of pEgr-TNFalpha gene radiotherapy on mice melanoma.

    abstract::In the present study, we constructed a pEgr-tumour necrosis factor-alpha (TNFalpha) plasmid and investigated its expression properties in B16 cells on exposure to ionizing irradiation and, furthermore, the effect of gene radiotherapy on a melanoma model. Firstly, the recombinant pEgr-TNFalpha plasmid was constructed a...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200506000-00007

    authors: Wu C,Li X,Tian M

    更新日期:2005-06-01 00:00:00